Valuation: HLS Therapeutics Inc.

Market Cap 88.24M 78.65M 72.86M 66.25M 124M 8.37B 126M 874M 344M 4.37B 331M 324M 13.98B P/E 2026 *
-14x
P/E 2027 * -41.4x
Enterprise Value 88.24M 78.65M 72.86M 66.25M 124M 8.37B 126M 874M 344M 4.37B 331M 324M 13.98B EV / Sales 2026 *
1.51x
EV / Sales 2027 * 1.36x
Free-Float
99.44%
Yield 2026 *
-
Yield 2027 * -
1 day-0.24%
1 week+0.99%
Current month-2.62%
1 month+3.02%
3 months-0.49%
6 months-12.04%
Current year-15.15%
1 week 4.03
Extreme 4.03
4.24
1 month 3.75
Extreme 3.75
4.43
Current year 3.56
Extreme 3.56
5.25
1 year 3.56
Extreme 3.56
5.62
3 years 3
Extreme 3
5.76
5 years 3
Extreme 3
20.52
10 years 3
Extreme 3
25.92
Manager TitleAgeSince
Chief Executive Officer 58 01/05/2023
Director of Finance/CFO 61 26/01/2024
Chief Tech/Sci/R&D Officer 61 01/06/2014
Director TitleAgeSince
Director/Board Member 58 12/03/2018
Chairman 48 22/06/2023
Director/Board Member 65 01/01/2021
Date Insider Type Main position Quantity % Market Cap. Importance
30/09/26 TaxCompany 1,000 0.0032% -
30/09/26 TaxCompany -1,000 0.0032% -
29/09/26 TaxCompany 2,000 0.0065% -
Change 5-day change 1-year change 3-year change Capi.($)
-0.24%+0.99%-27.22%-20.43% 88.24M
-1.33%+4.88%+53.33%+109.94% 1,120B
-0.69%-3.77%+31.01%+66.62% 616B
-0.96%+0.55%+21.81%+94.26% 504B
+0.24%+6.23%+33.98%+52.38% 367B
-1.59%-1.25%+66.39%+43.02% 360B
-0.40%+4.28%+19.17%+42.51% 288B
-0.37%+3.35%-1.26%+16.85% 258B
-1.75%+1.76%+40.09%+51.44% 234B
-2.00%+1.75%+24.34%+95.14% 194B
Average -0.63%+3.00%+26.16%+55.17% 394.1B
Weighted average by Cap. -0.61%+3.52%+36.92%+74.48%

Financials

2026 *2027 *
Net sales 58.34M 52M 48.17M 43.8M 82.19M 5.53B 83.54M 578M 227M 2.89B 219M 214M 9.24B 65.06M 57.99M 53.72M 48.85M 91.66M 6.17B 93.16M 644M 253M 3.22B 244M 239M 10.31B
Net income -5.47M -4.88M -4.52M -4.11M -7.71M -519M -7.83M -54.17M -21.3M -271M -20.52M -20.09M -866M -2.16M -1.93M -1.79M -1.63M -3.05M -205M -3.1M -21.44M -8.43M -107M -8.12M -7.95M -343M
Net Debt - -
Projected Income Statement - Annual - HLS Therapeutics Inc.
Logo HLS Therapeutics Inc.
HLS Therapeutics Inc. is a pharmaceutical company focused on the acquisition and commercialization of late-stage development, commercial stage promoted and established branded pharmaceutical products in the North American markets. It is engaged in addressing unmet needs in the treatment of psychiatric disorders and cardiovascular disease. Its products include Clozaril, CSAN Pronto, MyCare Psychiatry and Vascepa. Its Clozaril is an atypical antipsychotic indicated for the management of symptoms of treatment-resistant schizophrenia for the Canadian and United States markets. CSAN Pronto is designed to enhance and simplify the mandatory safety blood monitoring process for patients that are prescribed Clozaril. Vascepa capsules are a single-molecule prescription product for the treatment of cardiovascular disease.
Employees
85
Date Price Change Volume
20/10/26 CA$4.090 -0.24% 4,649
16/10/26 CA$4.100 -0.97% 15,342
15/10/26 CA$4.140 +0.98% 41,098
14/10/26 CA$4.100 +1.23% 19,178
13/10/26 CA$4.050 -0.98% 25,650
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
MarketScreener Ratings - HLS Therapeutics Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
2.899USD
Average target price
5.269USD
Spread / Average Target
+81.78%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - HLS Therapeutics Inc.